🧬 From observational science to engineering – this is the transformation we're driving in biology.

Latent-X has been available for over two weeks and we couldn't be more excited about the science already being done with it.

Our CEO @saakohl.bsky.social joined @bloomberg.com News Daybreak Europe today to talk why we're building it, and the impact it is having.

Watch here: tinyurl.com/yjzyhr23

🧬Latent-X is our first frontier model for protein design.

For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation.

Explore our best binders here: platform.latentlabs.com

More details on the breakthrough in this🧵

‘Latent Labs launches web-based AI model to democratize protein design.’

Thank you @techcrunch.com and Marina Temkin for the coverage.

Read the full story: tinyurl.com/Latent-X-Tec...

5 months from funding to shipping our first frontier model. Latent-X achieves state-of-the-art hit rates for macrocycles and mini-binders, with picomolar binding affinities — a breakthrough in de novo protein binder design.

Available now on our no-code platform!

Catch @saakohl.bsky.social's panel with Glen Gowers, Michael Curtis, Amber Salzman, and Oliver Barnes at the @financialtimes.com Biotech Summit this Thursday discussing what the future holds for AI-driven drug discovery.

Latent Labs is partnering with @awscloud.bsky.social to super‑charge generative AI for the life sciences. Together, we’ll scale access to protein design tools that help scientists discover breakthrough therapies faster.

"Latent Labs is building AI foundation models to 'make biology programmable', partnering with biotech and pharma to generate and optimize proteins."
Huge thanks to @techcrunch.com, our investors & supporters. Follow us as we push the frontiers of AI & biology.
techcrunch.com/2025/02/12/f...

"What if scientists could create the building blocks of new medicines completely from scratch, targeting diseases with precisely designed cures?"

Thank you @forbes.com & @davidprosser for the coverage:
www.forbes.com/sites/davidp...

"One of DeepMind’s Nobel-prize winning AlphaFold team has raised $50 million to launch his own venture designing new proteins, with the goal of “achieving computational mastery over biology”."
Thank you @thetimes.com and @richardtyler for featuring us: www.thetimes.com/business-mon...

"Simon Kohl, a scientist, has raised $50M to launch a startup to discover new drugs."
We’re grateful for the incredible response to our mission. Thank you @financialtimes.com, @hannahkuchler.bsky.social & @melissahei.bsky.social.
www.ft.com/content/9214...

I loved my time at DeepMind working on AlphaFold2 and to be there in Stockholm to watch Demis Hassabis and John Jumper accept the Nobel Prize was incredible.

We’ve built an exceptional founding team – and are hiring in London and San Francisco! Come join the likes of Alex Bridgland (AlphaFold 1, 2 & 3), Annette Obika-Mbatha (multiple DeepMind programs), Dave Yuan (Mammoth Bio) and amazing people from Microsoft, Google, Altos Labs, Stability AI and more.

Our Angels include Google Chief Scientist @jeffdean.bsky.social, Transformer architecture co-inventor and Cohere founder @aidangomez.bsky.social, and ElevenLabs founder Mati Staniszewski.

The funding includes our Series A co-led by Radical Ventures and Sofinnova Partners, with existing investors Pillar VC, Kindred Capital and 8VC participating alongside new investors Isomer Capital and Flying Fish.

Every biotech or pharma company searching for the best therapeutic molecules understands the role AI can play - but not all are in a position to develop their own advanced models. That’s where @latentlabs.bsky.social comes in.

Apply to access our tools or join the team www.latentlabs.com

It is clear protein design has the potential to transform medicine and scientific discovery. I believe Latent Labs will be the team to fully realize its potential. It’s a vast field and there’s so much still to do. Let’s go!

We are out of stealth with $50M in funding.

Join us on our moonshot mission of making biology programmable and reach out to work with us today.